Who Paid My Doc
Hal Roseman
Nashville, TN Medical Doctor
NPI 1366541302 CMS profile 197765
2400 Patterson St, Suite 218, Nashville, TN 37203
General payments
$78,792
Research payments
$108,006
Ownership & investment interest
$0
Research they led as principal investigator
$311,046
Through program year 2022, Hal Roseman of Nashville, TN is reported in the CMS Open Payments database as having received $78,792 across 144 general payments and $108,006 in research payments paid to them. Separately, studies naming them as principal investigator received $311,046 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2022 | General | $59 | 4 | |
| 2021 | General | $347 | 20 | |
| 2021 | Research | $7,514 | 2 | |
| 2020 | General | $4,009 | 29 | |
| 2020 | Research | $42,953 | 6 | |
| 2019 | General | $74,376 | 91 | |
| 2019 | Research | $57,539 | 10 |
Beside peers
- Hal Roseman
- Tennessee median
- Middle half of Tennessee
- National median
In program year 2025, general payments to Hal Roseman were reported at $0. Among 24,836 Tennessee profiles paid that year, the median was $199 and the middle half received between $54 and $728.
Show as a table
| Year | Hal Roseman | Tennessee median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $74,376 | $197 | $58–$789 | $163 |
| 2020 | $4,009 | $132 | $38–$484 | $114 |
| 2021 | $347 | $145 | $39–$541 | $132 |
| 2022 | $59 | $170 | $50–$642 | $149 |
| 2023 | $0 | $183 | $50–$668 | $160 |
| 2024 | $0 | $187 | $51–$700 | $164 |
| 2025 | $0 | $199 | $54–$728 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 13 billing codesPaid by Medicare
$5,000
Medicare patients
99
Services billed
114
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Diabetes | 51% | |
| Heart failure | 49% | |
| Arthritis | 43% | |
| Atrial fibrillation | 42% | |
| Ischemic heart disease | 40% | |
| Chronic kidney disease | 38% | |
| Depression | 33% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
162 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.